Since they already showed in both Phase 1b trials that there was an improvement in hearing and if the age-related hearing loss also shows improvement in hearing even though the severe hearing loss trial may not look as good, the FDA should allow them to go to the pivotal phase with their current delivery method as it will help millions of people who suffer from mild-moderate hearing loss. Just let FX-322 get the minimal approval and work on new delivery method later.Yeah this is what I mean. We should be focusing on initial approval regardless of whether the current combo reaches all the frequencies we want.
They will end up reformulating either way because the technology exists and multiple shots per ear is damn inconvenient for everyone. At that point we'll see the inner ear distribution we're looking for.
Why should mild-moderate hearing loss sufferers need to wait even longer due to the severe hearing loss trial not showing meaningful improvements. Lets get the minimal approval.